Evolus, Inc. Reports Third Quarter 2026 Global Net Revenue of $78.0 Million and Reaffirms Full-Year Revenue Guidance

Evolus, Inc. reported its financial results for the third quarter ended September 30, 2026, featuring global net revenue of $78.0 million, which represents a 13% increase over the third quarter of 2025. The total net revenue included $70.1 million of global toxin revenue and $7.9